Evaluation of Dupilumab in Children With Uncontrolled Asthma
Status:
Completed
Trial end date:
2020-08-26
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the efficacy of dupilumab in children 6 to less than (<) 12 years of age with
uncontrolled persistent asthma.
Secondary Objective:
To evaluate in children 6 to <12 years of age with uncontrolled persistent asthma:
- The safety and tolerability of dupilumab.
- The evaluate the effect of dupilumab in improving participant reported outcomes
including health related quality of life.
- The dupilumab systemic exposure and incidence of anti-drug antibodies.
- The evaluate the association between dupilumab treatment and pediatric immune responses
to vaccines: any vaccination for tetanus, diphtheria, pertussis and/or seasonal
trivalent/quadrivalent influenza vaccine.